CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.
about
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.Colony-stimulating factor 1 receptor blockade prevents fractionated whole-brain irradiation-induced memory deficitsPromotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling.SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactionsHigh Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunitiesPrioritization schema for immunotherapy clinical trials in glioblastoma.Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model.Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage.Functions of interleukin-34 and its emerging association with rheumatoid arthritis.B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.Innate immune mediators in cancer: between defense and resistance.Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.Rationally designed ligand-independent peptide inhibitors of TREM-1 ameliorate collagen-induced arthritis.Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation.Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment.CSF-1R regulates non-small cell lung cancer cells dissemination through Wnt3a signaling.Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.A drug development perspective on targeting tumor-associated myeloid cells.Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.Effects of IL-10 and Th 2 cytokines on human Mφ phenotype and response to CSF1R inhibitor.Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity.T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer.Prodrugs for colon-restricted delivery: Design, synthesis, and in vivo evaluation of colony stimulating factor 1 receptor (CSF1R) inhibitorsA miR-125b/CSF1-CX3CL1/tumor-associated macrophage recruitment axis controls testicular germ cell tumor growth
P2860
Q30275521-37FEB1B2-D41F-4A9C-B865-6B0721B6EA80Q30805782-64D04E8A-EFE0-4BB8-AA0B-4BA46AA6A85DQ33832775-F4CE1902-958B-4B66-A1CD-31034EFF0734Q34518758-1494C625-7DAE-4C92-BF4E-EE3A78C16027Q36162776-58735EF4-1A20-4BF1-AA60-7214F8433AA4Q36447553-9EA33F37-AF11-42CC-AD58-8302BEE70E72Q37078999-60DB019F-7AF5-4EC0-923B-647453D3C1A0Q37222132-2CC0FCB5-8A0B-4B03-BC38-E0F06A176046Q37735637-67809543-E520-413A-A73A-7269A129B880Q38667135-AF9E4B04-7D72-4C5C-8AFD-B4A0618091E7Q38880272-4D900FDC-AB17-476A-8430-34EFE5613214Q38934355-D7E1EB07-589B-4551-B3A7-B8B563A36EFDQ38966197-B23BA01F-7151-4518-8A8E-EEE848A943A3Q38991015-3060EC0E-4FEC-4DD2-9E6D-4536FB5552A0Q39022841-1C776524-1B01-484D-97CC-864A1FA48C1AQ42030573-F21AC7AC-6050-446E-897E-7870CAC28132Q42339950-71D4A498-0CF1-4E0D-B34A-EE44822FB0E6Q47144415-B1C6D6C5-8ECA-4E03-887E-CE5585CAFC0DQ47168980-6637B54B-F0CA-4CE0-9A39-6459B48A0264Q47404669-7725380E-E329-48E8-9E83-483D46F3EC12Q48652546-D9D3BA46-A0A3-46EE-9D91-5EBB983BB0ADQ49835172-8F55E16A-90C5-4C28-91CC-CCDC5CD774E3Q49973081-8BB47A0B-F449-440D-8ABD-1A9931D4777BQ50045161-F373ECF4-9310-4787-93EC-558915BAF2D8Q51705595-044A2459-E6E8-4854-8126-C8887894796FQ52593234-0A6B29FD-8DDB-4AF5-8125-FBA0C88699C7Q55316979-7FD009AB-D561-45E4-97CE-1C342431F505Q55322297-625AB5CE-BAC1-4AD5-905E-56E2D5B405A6Q57159795-199EE482-7E97-4273-AC21-4F12A17BD533Q58712402-44B1C15A-43EC-4C44-93BA-7F5C1F1C42B6
P2860
CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.
@en
type
label
CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.
@en
prefLabel
CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.
@en
P2093
P1476
CSF-1/CSF-1R targeting agents in clinical development for cancer therapy
@en
P2093
Carola H Ries
Dominik Rüttinger
Michael A Cannarile
P356
10.1016/J.COPH.2015.05.008
P50
P577
2015-06-04T00:00:00Z